Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0165-1875 as add-on to semaglutide for weight management in obesity
NCT04969939Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of NNC0165-1875 in obesity, sponsored by Novo Nordisk. Started Jul 2021; status: completed.
02
Drugs
NNC0165-1875
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04969939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969939.